NO985667D0 - FremgangsmÕte for fremstilling av legemiddelkomplekser - Google Patents
FremgangsmÕte for fremstilling av legemiddelkomplekserInfo
- Publication number
- NO985667D0 NO985667D0 NO985667A NO985667A NO985667D0 NO 985667 D0 NO985667 D0 NO 985667D0 NO 985667 A NO985667 A NO 985667A NO 985667 A NO985667 A NO 985667A NO 985667 D0 NO985667 D0 NO 985667D0
- Authority
- NO
- Norway
- Prior art keywords
- spacer
- drug compound
- bound
- carboxyl groups
- drug
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 9
- 229940079593 drug Drugs 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000006850 spacer group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 150000004676 glycans Chemical class 0.000 abstract 4
- 229920001282 polysaccharide Polymers 0.000 abstract 4
- 239000005017 polysaccharide Substances 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 238000006243 chemical reaction Methods 0.000 abstract 2
- -1 amine salt Chemical class 0.000 abstract 1
- 125000000686 lactone group Chemical group 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14452296 | 1996-06-06 | ||
| PCT/JP1997/001915 WO1997046261A1 (fr) | 1996-06-06 | 1997-06-05 | Procede de fabrication de complexes medicamenteux |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985667D0 true NO985667D0 (no) | 1998-12-04 |
| NO985667L NO985667L (no) | 1999-02-04 |
| NO323626B1 NO323626B1 (no) | 2007-06-18 |
Family
ID=15364300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985667A NO323626B1 (no) | 1996-06-06 | 1998-12-04 | Fremgangsmate for fremstilling av et medikamentkompleks |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6291671B1 (no) |
| EP (1) | EP0955064B1 (no) |
| JP (1) | JP4137184B2 (no) |
| CN (1) | CN1227034C (no) |
| AT (1) | ATE273716T1 (no) |
| AU (1) | AU723442B2 (no) |
| CA (1) | CA2257233A1 (no) |
| DE (1) | DE69730352T2 (no) |
| DK (1) | DK0955064T3 (no) |
| EA (1) | EA001897B1 (no) |
| ES (1) | ES2229355T3 (no) |
| ID (1) | ID17243A (no) |
| NO (1) | NO323626B1 (no) |
| PT (1) | PT955064E (no) |
| TW (1) | TW409058B (no) |
| WO (1) | WO1997046261A1 (no) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| HK1040052B (zh) * | 1998-05-22 | 2006-09-15 | 第一制药株式会社 | 药物复合物 |
| EP1298145A4 (en) * | 2000-06-29 | 2004-12-08 | Daiichi Seiyaku Co | DDS CONNECTION AND METHOD FOR PRODUCING THE SAME |
| EP1401875A4 (en) * | 2001-05-04 | 2005-01-26 | Univ Utah Res Found | HYALURONIC ACID-CONTAINING BIOKON JUGATES: TARGETED DELIVERY OF ANTIBODIES TO CANCER CELLS |
| US20030049253A1 (en) * | 2001-08-08 | 2003-03-13 | Li Frank Q. | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines |
| US20050169883A1 (en) * | 2002-05-06 | 2005-08-04 | Prestwich Glenn D. | Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| US7691830B2 (en) * | 2005-02-17 | 2010-04-06 | Clive Elson | Method and composition for treatment of a mucosal tissue disorder |
| JP5296531B2 (ja) | 2005-05-05 | 2013-09-25 | センシエント フレイバーズ エルエルシー | βグルカン及びマンナンの製造 |
| EP1905456A4 (en) * | 2005-07-06 | 2010-12-22 | Seikagaku Kogyo Co Ltd | PHARMACEUTICAL LIGHT-NETWORKED HYALURONIC DERIVATIVE GEL |
| ITPD20050242A1 (it) | 2005-08-03 | 2007-02-04 | Fidia Farmaceutici | Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico |
| CN1973902B (zh) * | 2006-12-12 | 2010-11-10 | 东北师范大学 | 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法 |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| DK2576638T3 (da) | 2010-05-25 | 2021-03-15 | Syndevrx Inc | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf |
| DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| CN105431426A (zh) | 2013-04-10 | 2016-03-23 | 新德发制药有限公司 | Metap2抑制剂和治疗肥胖症的方法 |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| LT3424955T (lt) | 2013-12-25 | 2025-06-25 | Daiichi Sankyo Company, Limited | Anti-trop2 antikūno ir vaisto konjugato gamybos būdas |
| SI3466976T1 (sl) | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Company, Limited | Anti-her2 konjugat protitelesa-zdravila |
| JP6612738B2 (ja) | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| KR102399277B1 (ko) | 2014-04-10 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| US9969722B2 (en) | 2015-12-10 | 2018-05-15 | Syndevrx, Inc. | Fumagillol derivatives and polymorphs thereof |
| CN108697807B (zh) | 2016-01-11 | 2021-11-26 | 辛德弗雷克斯公司 | 代谢功能障碍引起的肿瘤的治疗 |
| BR112019011794A2 (pt) | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| CA3050668C (en) | 2017-01-17 | 2023-08-15 | Daiichi Sankyo Company, Limited | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| TW202532102A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| BR112020003466B1 (pt) | 2017-08-31 | 2023-12-12 | Daiichi Sankyo Company, Limited | Métodos de produção de composto, e, composto |
| ES3057444T3 (en) | 2017-08-31 | 2026-03-02 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| TW202537643A (zh) | 2018-07-31 | 2025-10-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之用途 |
| CN113453721B (zh) | 2018-10-26 | 2025-09-16 | 辛德弗雷克斯公司 | Metap2抑制剂的生物标志物及其应用 |
| TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5746920A (en) * | 1980-09-03 | 1982-03-17 | Kyosei Seiyaku Kk | Drug for digestive tract |
| DE3152319C2 (de) | 1980-09-03 | 1986-05-07 | Kyosei Pharmaceutical Co., Ltd., Hokkaido | Verwendung einer Lösung eines Salzes der Alginsäure zur Behandlung von Strahlenschäden und Ulcera |
| JPS59220197A (ja) | 1983-05-30 | 1984-12-11 | Snow Brand Milk Prod Co Ltd | 新規な含窒素多糖体およびその製造方法 |
| JP2604930B2 (ja) * | 1990-12-14 | 1997-04-30 | 株式会社ディ・ディ・エス研究所 | ヒアルロン酸およびコンドロイチン誘導体 |
| CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| ES2117664T3 (es) | 1991-02-21 | 1998-08-16 | Drug Delivery System Inst Ltd | Carboximetilmanoglucanos y derivados de los mismos. |
| JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| EP0640622B1 (en) | 1993-02-26 | 2000-08-09 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
| JPH0784481A (ja) | 1993-06-26 | 1995-03-31 | Ricoh Co Ltd | 画像形成装置 |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6299881B1 (en) * | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
-
1997
- 1997-05-31 TW TW086107456A patent/TW409058B/zh not_active IP Right Cessation
- 1997-06-05 CA CA002257233A patent/CA2257233A1/en not_active Abandoned
- 1997-06-05 PT PT97924326T patent/PT955064E/pt unknown
- 1997-06-05 EP EP97924326A patent/EP0955064B1/en not_active Expired - Lifetime
- 1997-06-05 AT AT97924326T patent/ATE273716T1/de not_active IP Right Cessation
- 1997-06-05 US US09/147,341 patent/US6291671B1/en not_active Expired - Fee Related
- 1997-06-05 ID IDP971929A patent/ID17243A/id unknown
- 1997-06-05 DK DK97924326T patent/DK0955064T3/da active
- 1997-06-05 DE DE69730352T patent/DE69730352T2/de not_active Expired - Lifetime
- 1997-06-05 CN CNB971971153A patent/CN1227034C/zh not_active Expired - Fee Related
- 1997-06-05 WO PCT/JP1997/001915 patent/WO1997046261A1/ja not_active Ceased
- 1997-06-05 JP JP50042298A patent/JP4137184B2/ja not_active Expired - Fee Related
- 1997-06-05 ES ES97924326T patent/ES2229355T3/es not_active Expired - Lifetime
- 1997-06-05 AU AU29788/97A patent/AU723442B2/en not_active Ceased
- 1997-06-05 EA EA199900002A patent/EA001897B1/ru not_active IP Right Cessation
-
1998
- 1998-12-04 NO NO19985667A patent/NO323626B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2229355T3 (es) | 2005-04-16 |
| EP0955064A1 (en) | 1999-11-10 |
| EA199900002A1 (ru) | 1999-08-26 |
| PT955064E (pt) | 2004-10-29 |
| AU2978897A (en) | 1998-01-05 |
| WO1997046261A1 (fr) | 1997-12-11 |
| US6291671B1 (en) | 2001-09-18 |
| CN1227034C (zh) | 2005-11-16 |
| NO985667L (no) | 1999-02-04 |
| EP0955064B1 (en) | 2004-08-18 |
| DE69730352T2 (de) | 2005-09-08 |
| TW409058B (en) | 2000-10-21 |
| AU723442B2 (en) | 2000-08-24 |
| CA2257233A1 (en) | 1997-12-11 |
| ID17243A (id) | 1997-12-11 |
| ATE273716T1 (de) | 2004-09-15 |
| DE69730352D1 (de) | 2004-09-23 |
| EA001897B1 (ru) | 2001-10-22 |
| JP4137184B2 (ja) | 2008-08-20 |
| DK0955064T3 (da) | 2004-12-06 |
| NO323626B1 (no) | 2007-06-18 |
| CN1227500A (zh) | 1999-09-01 |
| EP0955064A4 (en) | 2000-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO985667D0 (no) | FremgangsmÕte for fremstilling av legemiddelkomplekser | |
| FI893467L (fi) | Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi | |
| NO985666L (no) | Medikamentkompleks | |
| FI885623A7 (fi) | Menetelmä lääkeaineina käyttökelpoisten substituoitujen propaani-fosfiinihappoyhdisteiden valmistamiseksi | |
| EA199800811A1 (ru) | Способ получения нитробифенилов | |
| US3971700A (en) | Process for the enzymatic resolution of DL-phenyl glycine amide into its optically active antipodes | |
| HU9301765D0 (en) | Compounds of cerium (iv) as well as their production and application | |
| HUT44042A (en) | Process for preparing renin inhibitor peptides, amino acid and aminoaldehyde derivatives, as well as pharmaceuticals comprising renin inhibitor peptides | |
| BG50164A3 (en) | Method for preparing of amicacine | |
| FI861655L (fi) | Menetelmä lääkeaineina käyttökelpoisten griseoliinihapon johdannaisten valmistamiseksi | |
| CA2009295A1 (en) | Process for the enzymatic resolution of 2-amino-4-methylphosphinobutyric acid derivatives | |
| EP1336603A4 (en) | METHOD FOR INTRODUCING AN AMINO GROUP AND PROCESS FOR SYNTHESIZING AMINO ACID | |
| PT83837A (de) | Verfahren zur herstellung von peptiden unter der verwendung von perchloraten | |
| EP0344791A3 (en) | Process for the enzymatic resolution of the optical isomers of racemic ester derivatives of 3-mercapto-2-alkyl-propionic acid | |
| DE68925951D1 (de) | Chemisches Verfahren zur Herstellung des Antibiotikums L 17392 (Deglukoteicoplanin) und dessen Salze | |
| FI895635A0 (fi) | Menetelmä biokatalysaattorien valmistamiseksi | |
| EP0226132A3 (de) | Dipeptide mit C-terminalem Phosphinothricin, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses | |
| FI885638A0 (fi) | Menetelmä lääkeaineina käyttökelpoisten griseoliinihappomonoesterijohdannaisten valmistamiseksi | |
| AU629008B2 (en) | Compounds from biopolymrs and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof | |
| GR3002989T3 (en) | Process for the production of n-acylated mercapto-alpha-amino acids | |
| NO20011031L (no) | Fremgangsmåte for fremstilling av N-beskyttede azetidin-2- karboksylsyrer (AzeOHs) | |
| ATE92483T1 (de) | Verfahren zur herstellung von thiophenderivaten sowie dihydrothiophen-1-oxide. | |
| RU95115861A (ru) | Способ получения мурамилпептидов | |
| GB1359451A (en) | Process for producing desacetoyxycephalosporin derivatives | |
| BR8901324A (pt) | Processos para a preparacao de um metil ester de alfa-l-aspartil-l-fenilalanina com n protegido,para a preparacao de um anidrido aspartico com n protegido e para a preparacao de anidrido n-benziloxicarbonil-l-aspartico |